Project | SCLC | NSCLC | P Value | LADC | LSCC | P Value |
---|---|---|---|---|---|---|
Before treatment | ||||||
MMP-2 (ng/L) | 182.93 ± 12.24 | 181.52 ± 11.67 | 0.48 | 180.22 ± 10.37 | 181.05 ± 12.14 | 0.65 |
MMP-9 (ng/L) | 206.17 ± 21.43 | 207.88 ± 21.86 | 0.64 | 207.61 ± 21.59 | 208.20 ± 21.54 | 0.87 |
CD4+% | 33.63 ± 3.76 | 33.00 ± 4.09 | 0.36 | 32.55 ± 3.64 | 33.17 ± 3.93 | 0.32 |
CD8+% | 30.87 ± 3.03 | 30.46 ± 3.34 | 0.46 | 30.25 ± 3.13 | 30.77 ± 3.03 | 0.31 |
CD4+/CD8+ | 1.20 ± 0.22 | 1.15 ± 0.23 | 0.20 | 1.17 ± 0.21 | 1.13 ± 0.21 | 0.25 |
After treatment | ||||||
MMP-2 (ng/L) | 35.6 ± 1.02 | 30.52 ± 2.12 | < 0.0001 | 30.71 ± 2.31 | 30.78 ± 1.86 | 0.85 |
MMP-9 (ng/L) | 35.37 ± 1.25 | 31.08 ± 1.52 | < 0.0001 | 31.13 ± 1.47 | 30.86 ± 1.3 | 0.25 |
CD4+% | 38.15 ± 4.97 | 37.78 ± 5.08 | 0.66 | 37.33 ± 4.63 | 37.81 ± 5.05 | 0.54 |
CD8+% | 27.22 ± 3.66 | 26.93 ± 3.71 | 0.64 | 26.51 ± 3.29 | 27.13 ± 3.51 | 0.27 |
CD4+/CD8+ | 1.36 ± 0.18 | 1.33 ± 0.21 | 0.39 | 1.30 ± 0.18 | 1.34 ± 0.20 | 0.20 |